Citations

Clear

2358 citation(s) found for "Yu, Long".

Neuro-Oncology Practice Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma
Stocksdale, Brian, Nagpal, Seema , Hixson, John , Johnson, Derek R. , Rai, Prashant , Shivaprasad, Akhil , Tremont‐Lukats, Ivo W. , Hixson, John D , Johnson, Derek R , Nagpal, Seema

Mayo Clinic

Neuro-Oncology Practice | May 20, 2020 | Volume: 7 | Issue: 6 | Pages: 583-588

10.1093/nop/npaa026 | PMID 33312673 Get It

Abstract Patients with primary brain tumors often experience seizures, which can be the presenting symptom or occur for the first time at any point along the illness trajectory. In addition to causing morbidity, seizures negatively affect independence and quality of life in other ways, for example, by leading to loss of driving privileges. Long-term therapy with antiepileptic drugs (AEDs) is the standard of care in brain tumor patients with seizures, but the role of prophylactic AEDs in seizure-naive patients remains controversial. In this article, experts in the field discuss the issues of AED efficacy and toxicity, and explain their differing recommendations for routine use of prophylactic AEDs.
Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome
Lahrouchi, Najim , Crotti, Lia , Mizusawa, Yuka , Postema, Pieter G. , Beekman, Leander , Walsh, Roddy , Hasegawa, Kanae , Barc, Julien , Ernsting, Marko, Turkowski, Kari L. , Mazzanti, Andrea , Beckmann, Britt M., Diamant, Ulla‐Britt , Kucho, Yu, Robyns, Tomas , Winbo, Annika , Jabbari, Reza , Lubitz, Steven A., Steinfurt, Johannes , Rudic, Boris , Shoemaker, Moore B., Weeke, Peter , Davies, Brianna , Andorin, Antoine , Hofman, Nynke , Pedrazzini, Matteo , Tester, David J. , Bos, J. Martijn , Platonov, Pyotr G. , Stallmeyer, Birgit, Zumhagen, Sven, Nannenberg, Eline A., Veldink, Jan H., Berg, Leonard H. van den, Al‐Chalabi, Ammar , Shaw, Christopher E. , Shaw, Pamela J. , Morrison, Karen , Müller‐Nurasyid, Martina , Cusi, Daniele , Lathrop, Mark , Munter, Markus, Aung, Tin , Ozaki, Mineo , Lichtner, Peter , Tintelen, J. Peter van , Hoedemaekers, Yvonne M., Napolitano, Carlo , Gourraud, Jean‐Baptiste , Makiyama, Takeru , Ohno, Seiko , Itoh, Hideki , Roden, Dan M. , Saenen, Johan , Borggrefe, Martin, Odening, Katja E. , Ellinor, Patrick T., Tfelt‐Hansen, Jacob , Skinner, Jonathan R. , Berg, Maarten P. van den , Makita, Naomasa , Breckpot, Jeroen , Yoshinaga, Masao , Behr, Elijah R. , Rydberg, Annika , Aiba, Takeshi , Priori, Silvia G. , Newton‐Cheh, Christopher , Schulze‐Bahr, Eric , Horie, Minoru , Wilde, Arthur A.M. , Tanck, Michael W.T. , Bezzina, Connie R. , Lubitz, Steven A. , Crotti, Lia , Makita, Naomasa , Horie, Minoru , Behr, Elijah Raphael , van Tintelen, J Peter , Odening, Katja E , Bos, Johan M , Tanck, Michael , Barc, Julien , Tfelt-Hansen, Jacob , Skinner, Jonathan R , van den Berg, Maarten P , Robyns, Tomas , Lubitz, Steven A , Al-Chalabi, Ammar , Bezzina, Connie R , Gourraud, Jean-Baptiste , Mazzanti, Andrea , Postema, Pieter G , Priori, Silvia , Walsh, Roddy , Tadros, Rafik , Beckmann, Britt-Maria, Shimamoto, Keiko , Wijeyeratne, Yanushi D. , Ishikawa, Taisuke , Arbelo, Elena , Christiansen, Michael , Loeys, Bart , Pfeiffer, Ryan D. , Dagradi, Federica , Sarquella-Brugada, Georgia , Campuzano, Óscar , Berg, Leonard H. van den , Andersen, Peter Munch , Barlassina, Cristina , Galán, Pilar , Werge, Thomas Mears , Ribasés, Marta , Khor, Chiea Chuen , Meitinger, Thomas , Denjoy, Isabelle , Leenhardt, Antoine , Shimizu, Wataru , Schott, Jean‐Jacques , Ohno, Seiko , Krahn, Andrew D. , Antzelevitch, Charles , Roden, Dan M. , Ellinor, Patrick T. , Olesen, Morten S. , Brugada, Josép , Brugada, Ramón , Aiba, Takeshi , Kääb, Stefan , Guicheney, Pascale , Tan, Hanno L. , Ackerman, Michael , Schwartz, Peter J. , Probst, Vincent

Mayo Clinic

Circulation | May 20, 2020 | Volume: 142 | Issue: 4 | Pages: 324-338

10.1161/circulationaha.120.045956 | PMID 32429735 Get It

Background: Long QT syndrome (LQTS) is a rare genetic disorder and a major preventable cause of sudden cardiac death in the young. A causal rare genetic variant with large effect size is identified in up to 80% of probands (genotype positive) and cascade family screening shows incomplete penetrance of genetic variants. Furthermore, a proportion of cases meeting diagnostic criteria for LQTS remain genetically elusive despite genetic testing of established genes (genotype negative). These observations raise the possibility that common genetic variants with small effect size contribute to the clinical picture of LQTS. This study aimed to characterize and quantify the contribution of common genetic variation to LQTS disease susceptibility. Methods: We conducted genome-wide association studies followed by transethnic meta-analysis in 1656 unrelated patients with LQTS of European or Japanese ancestry and 9890 controls to identify susceptibility single nucleotide polymorphisms. We estimated the common variant heritability of LQTS and tested the genetic correlation between LQTS susceptibility and other cardiac traits. Furthermore, we tested the aggregate effect of the 68 single nucleotide polymorphisms previously associated with the QT-interval in the general population using a polygenic risk score. Results: Genome-wide association analysis identified 3 loci associated with LQTS at genome-wide statistical significance ( P <5×10 −8 ) near NOS1AP , KCNQ1 , and KLF12 , and 1 missense variant in KCNE1 (p.Asp85Asn) at the suggestive threshold ( P <10 −6 ). Heritability analyses showed that ≈15% of variance in overall LQTS susceptibility was attributable to common genetic variation ( h2SNP 0.148; standard error 0.019). LQTS susceptibility showed a strong genome-wide genetic correlation with the QT-interval in the general population (r g =0.40; P =3.2×10 −3 ). The polygenic risk score comprising common variants previously associated with the QT-interval in the general population was greater in LQTS cases compared with controls ( P <10−13), and it is notable that, among patients with LQTS, this polygenic risk score was greater in patients who were genotype negative compared with those who were genotype positive ( P <0.005). Conclusions: This work establishes an important role for common genetic variation in susceptibility to LQTS. We demonstrate overlap between genetic control of the QT-interval in the general population and genetic factors contributing to LQTS susceptibility. Using polygenic risk score analyses aggregating common genetic variants that modulate the QT-interval in the general population, we provide evidence for a polygenic architecture in genotype negative LQTS.
Impact of Post-operative Complications after Cardiac Surgery on Long-term Survival
Pahwa, Siddharth , Bernabei, Annalisa, Stulak, John, Greason, Kevin L. , Pochettino, Alberto , Daly, Richard C. , Bagameri, Gabor, Viehman, Jason K., Schaff, Hartzell V. , Dearani, Joseph A. , King, Katherine S. , Crestanello, Juan A.

Mayo Clinic

No container title available | May 18, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.158977808.89830126 Get It

Background – The impact of post-operative complications on long-term survival is not well characterized. We sought to study the prevalence of post-operative complications after cardiac surgery and their impact on long-term survival. Methods – Operative survivors (n=26,221) who underwent coronary artery bypass grafting (CABG) (n=13054, 49.8%), valve surgery (n=8667, 33.1%) or combined CABG and valve surgery (n=4500, 17.2%) from 1993 to 2019 were included in the study. Records were reviewed for post-operative complications and long-term survival. The associations between post-operative complications and survival were assessed using a Cox-proportional model. Results – Complications occurred in 17,463 (66.6%) of 26,221 operative survivors. A total of 17 post-operative complications were analyzed. Post-operative blood product use was the commonest (n=12397, 47.3%), followed by atrial fibrillation (n=8399, 32.0%), prolonged ventilation (n=2336, 8.9%), renal failure (n=870, 3.3%), re-operation for bleeding (n=859, 3.3%) and pacemaker/ICD insertion (n=795, 3.0%). Stroke (HR 1.55, 95%CI 1.36-1.77), renal failure (HR 1.45, 95% CI 1.33-1.58) anticoagulant-related events (HR 1.26, 95%CI 1.02-1.56) and pneumonia (HR 1.23, 95%CI 1.11-1.36) had the strongest impact on long-term survival. Long-term survival decreased as the number of post-operative complications increased. Conclusions – Post-operative complications after cardiac surgery significantly impact outcomes that extend beyond the post-operative period. The presence, number and type of post-operative complications adversely impact long-term survival. Stroke, renal failure, anticoagulant-related events and pneumonia are particularly associated with poor long-term survival.
Desmoplastic Fibroblastoma: An Uncommon Tumor With a Relatively Characteristic MRI Appearance
Kresse, Maxine E. , Fox, Michael G. , Long, Jeremiah R. , Murphey, Mark D. , Kransdorf, Mark J. , Flug, Jonathan A.

Mayo Clinic

American Journal of Roentgenology | May 14, 2020 | Volume: 215 | Issue: 1 | Pages: 178-183

10.2214/ajr.19.22163 | PMID 32406775 Get It

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey
Hurley, Patricia A. , Kim, Edward S. , Nowakowski, Grzegorz S. , Schilsky, Richard L. , Hurley, Patricia , Waterhouse, David , Harvey, R. Donald , Levit, Laura A. , Klepin, Heidi D. , Mileham, Kathryn Finch , Schenkel, Caroline , Davis, Courtney , Bruinooge, Suanna S.

Mayo Clinic

JCO Oncology Practice | May 12, 2020 | Volume: 16 | Issue: 7 | Pages: 417-421

10.1200/op.20.00275 | PMID 32396491 Get It

The coronavirus disease 2019 (COVID-19) pandemic has disrupted all aspects of clinical care, including cancer clinical trials. In March 2020, ASCO launched a survey of clinical programs represented on its Cancer Research Committee and Research Community Forum Steering Group and taskforces to learn about the types of changes and challenges that clinical trial programs were experiencing early in the pandemic. There were 32 survey respondents; 14 represented academic programs, and 18 represented community-based programs. Respondents indicated that COVID-19 is leading programs to halt or prioritize screening and/or enrollment for certain clinical trials and cease research-only visits. Most reported conducting remote patient care where possible and remote visits and monitoring with sponsors and/or contract research organizations (CROs); respondents viewed this shift positively. Numerous challenges with conducting clinical trials were reported, including enrollment and protocol adherence difficulties with decreased patient visits, staffing constraints, and limited availability of ancillary services. Interactions with sponsors and CROs about modifying trial procedures were also challenging. The changes in clinical trial procedures identified by the survey could serve as strategies for other programs attempting to maintain their clinical trial portfolios during the COVID-19 pandemic. Additionally, many of the adaptations to trials made during the pandemic provide a long-term opportunity to improve and transform the clinical trial system. Specific improvements could be expanded use of more pragmatic or streamlined trial designs, fewer clinical trial–related patient visits, and minimized sponsor and CRO visits to trial programs.
Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States
Raffals, Laura H., Long, Millie D. , Syal, Gaurav , Kayal, Maia , Cohen, Benjamin L., Deepak, Parakkal , Sandler, Robert S. , Raffals, Laura, Kayal, Maia , Deepak, Parakkal , Sandler, Robert S , Barnes, Edward L. , Ananthakrishnan, Ashwin N. , Pekow, Joel , Colombel, Jean‐Frédéric , Herfarth, Hans

Mayo Clinic

Crohn's & Colitis 360 | May 8, 2020 | Volume: 2 | Issue: 3 | Pages: No page available

10.1093/crocol/otaa039 | PMID 32744536 Get It

AbstractBackgroundGaps exist in our understanding of the clinical course of pouch-related disorders.MethodsWe evaluated baseline disease activity and longitudinal treatment patterns among patients with inflammatory conditions of the pouch.ResultsAmong 468 patients with an ileal pouch-anal anastomosis (IPAA), 94 (20%) had acute pouchitis, 96 (21%) had chronic pouchitis, and 192 (41%) had Crohn disease of the pouch. Following an IPAA, 38% of patients were treated with a biologic and 11% underwent inflammatory bowel disease- or bowel-related surgery.ConclusionsTreatment patterns after IPAA indicate that pouch-related disorders have a significant impact on individual patients and the healthcare system.
SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
Khan, Aliya , Vokes, Tamara , Rubin, Mishaela R. , Erikson, Erik H., Marcocci, Claudio , Ahmed, Intekhab, Mourya, Sanchita, Markova, Denka, Karpf, David, Rejnmark, Lars , Schwarz, Peter , Clarke, B.L. , Hofbauer, Lorenz C. , Erikson, Erik, Palermo, Andrea , Pagotto, Uberto

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.2209 Get It

Abstract Background: Hypoparathyroidism (HP) is caused by a deficiency in parathyroid hormone (PTH), which leads to hypocalcemia and hyperphosphatemia. Standard of care (SoC), i.e. large doses of calcium (Ca) and active vitamin D, worsens hypercalciuria and increases the serum Ca (sCa) x serum phosphate (sP) product. Studies have shown that continuous subcutaneous infusion of PTH(1-34) normalizes sCa, sP, serum magnesium, urine Ca (uCa) and bone turnover better than SoC or once- or twice-daily injections of PTH in HP patients. TransCon PTH, an investigational long-acting prodrug of PTH (1-34) transiently bound to an inert carrier via a linker, is under development as a potential once-daily replacement therapy for HP. Under physiological conditions, linker auto-cleavage occurs, releasing active PTH at a controlled rate with ~60 hour half-life. Phase 1 trial results demonstrated that once-daily TransCon PTH provided a flat, infusion like profile within the normal range of PTH 24 hours per day, increasing sCa while controlling uCa and decreasing sP, with no evidence of bone anabolic activity. Phase 2 Design: PaTH Forward is a global phase 2 trial evaluating the safety, tolerability, and efficacy of TransCon PTH in adult subjects with HP. Patients with HP treated with SoC were randomized at sites worldwide to daily TransCon PTH 15, 18 or 21 µg PTH(1-34) or daily blinded placebo via pen-injector for 4 weeks. The primary composite endpoint requires 1) normal albumin-adjusted sCa, and 2) normal Fractional Excretion of Ca (or ≥50% decrease from baseline), and 3) not taking active D, and 4) taking ≤1000 mg/d of Ca. After four weeks, all subjects enter an open-label extension period with the opportunity to receive TransCon PTH individually optimized to doses of 6 to 30 µg daily to evaluate long-term safety and efficacy. Other endpoints include the impact of treatment on patient experience, CaxP product, bone turnover markers, and bone mass by DXA and TBS to confirm the lack of anabolic effect. Preliminary Results: Approximately 55 subjects are expected to be randomized and dosed. Preliminary diary data on the initial 8 subjects completing 4 weeks of follow-up in the extension trial shows that all have discontinued SoC. Additional information will be presented at ENDO 2020. The Phase 2 trial is designed to inform the starting dose for a global pivotal phase 3 trial and evaluate TransCon PTH as a “true” PTH replacement therapy.
SAT-170 Clinical Course of Adrenal Myelolipoma: A Long-Term Longitudinal Follow-Up Study
Raman, Ram, Lazik, Natalia, Ariza-Iniguez, Nicole, McKenzie, Travis J. , Hamidi, Oksana , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | May 8, 2020 | Volume: 4 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaa046.1257 Get It

Abstract Myelolipoma is the second most common adrenal tumor. Yet, systematic approach to these tumors remains poorly defined. Thus, we aimed to describe natural history of myelolipoma and to identify predictors of tumor growth and need for surgery. We conducted a retrospective longitudinal follow-up study of consecutive patients with myelolipoma. A total of 321 myelolipomas (median size, 2.3 cm [range, 0.5-18.0]) were diagnosed in 305 patients at median age of 63 years (25-87). Most myelolipomas were discovered incidentally (86.6%), whereas others were discovered on imaging done for cancer staging (8.8%) or during workup of mass effect symptoms (4.6%). Median duration of follow-up was 54 months (range, 0.03-267). Compared with myelolipomas &lt;6 cm, tumors ≥6 cm were more likely to be right-sided (59% vs 41%, P=0.02), bilateral (21% vs 3%, P &lt;.0001), cause mass effects symptoms (32% vs 0%, P&lt;.0001), have radiographic hemorrhagic changes (14% vs 1%, P&lt;.0001), and undergo adrenalectomy (52% vs 5%, P&lt;.0001). There was no difference in sex or age at diagnosis between the groups. Hemorrhagic changes were noted in 9 (3.0%) patients with median tumor size of 7.0 cm (range, 1.8-18.0). Concomitant adrenal hormone excess was diagnosed in 12/126 (9.5%) patients. Primary aldosteronism was noted in 9 patients: due to concomitant ipsilateral (n=3) or contralateral adrenocortical adenoma (n=3), or bilateral idiopathic adrenal hyperplasia (n=3). Autonomous cortisol excess was noted in 3 patients: due to concomitant contralateral (n=2) or ipsilateral adrenocortical adenoma (n=1). Of 162 patients with ≥6 months of imaging follow-up, tumor size change ranged from -10 to 115 mm (median, 0 mm) and tumor growth rate ranged from -5.6 to 140 mm/year (median, 0 mm/year). Tumor growth ≥1.0 cm (n=26, 16.0%) was associated with larger initial tumor size (3.6 vs 2.3 cm, P=0.02) and hemorrhagic changes on imaging (12% vs 2%, P=0.007), compared with &lt;1 cm size change. Myelolipomas with ≥1.0 cm growth were more likely to undergo adrenalectomy (35% vs 8%, P&lt;.0001). Among 37 (12%) patients that underwent adrenalectomy for myelolipoma, surgical indications included: large tumor size/tumor growth (32%), diagnostic surgery (27%), mass effect symptoms (14%), concomitant ipsilateral tumor leading to hormonal excess (11%), acute hemorrhage (8%), and concomitant resection during non-adrenal surgery (8%). In conclusion, most myelolipomas are discovered incidentally, whereas myelolipomas ≥6 are more likely to cause mass effect symptoms, have radiographic hemorrhagic changes, and more commonly undergo resection. Hormonal excess is rare and is usually attributed to concomitant adrenocortical adenoma or hyperplasia. Tumor growth ≥1.0 cm is associated with larger myelolipoma and presence of hemorrhagic changes. Surgical resection should be considered in symptomatic patients with large tumors, evidence of hemorrhage, or tumor growth.
Is Lutikizumab, an Anti–Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis
Cao, Ziqin , Hu, Xutao , Zhou, Jian , Wu, Tong , Aili, Dilihumaer, Long, Zeling , Sun, Jingjing, Wu, Ren , Hu, Xutao, Zhou, Jian, Li, Yihan , Wang, Wanchun

Mayo Clinic

No container title available | April 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-23372/v1 Get It

Abstract OBJECTIVEOsteoarthritis (OA) is the most common form of joint disease which usually affects load-bearing joints such as hip and knee joints. Most guidelines recommend the use non-steroidal anti-inflammatory drugs (NSAIDs), duloxetine and tramadol for the non-operative treatment of OA, the use of them is limited by the tolerability and safety concerns. Lutikizumab is a novel anti–IL-1α/β dual variable domain immunoglobulin that can simultaneously binds and inhibits IL-1α and IL-1β to relieve the pain and dysfunction symptoms. We conducted this network meta-analysis to comprehensively compare the clinical efficacy and safety of lutikizumab with other drugs recommended by guidelines.DESIGNSystematic review and Bayesian network meta-analysis.DATA SOURCESAll eligible studies in PubMed, CKNI, EMBASE and Web of Science databases, from January 2000 to January 2020.METHODSBayesian network and conventional meta-analyses were conducted. Pain relief, function improvement and risk of adverse effects (AEs) were assessed.RESULTS24 articles with 11858 patients were included. Lutikizumab showed no benifit compared with placebo for both pain relief (SMD 1.11, 95% CI [-2.29 to 4.52]) and function improvement (SMD 0.992, 95% CI [-0.433 to 4.25]). Lutikizumab and all other drugs are of favorable tolerance for patients in treatment of OA compared with placebo.CONCLUSIONSThe results show that lutikizumab, the new anti–Interleukin-1α/β dual variable domain immunoglobulin, did not improve pain or function in the comparison with placebo. Selective cox-2 inhibitors remain the most effective and safest treatment for osteoarthritis. More high-quality trials are still needed to reconfirm the findings of this study.
Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial
Brannagan, Thomas H., Wang, A. K., Coelho, Teresa , Polydefkis, Michael , Dyck, P. James B. , Barroso, Fábio , Merlini, Giampaolo , Hughes, Stephen G. , Kwoh, Jesse, Jung, Shiangtung W., Guthrie, Spencer , Pollock, M. , Benson, M. D., investigators, for the NEURO‐TTR open‐label extension, Pinto, Marcus Vinícius , Campistol, Josep M. , Gámez, Josep , Brannagan, T H , Merlini, Giampaolo , Pinto, Marcus V , Waddington‐Cruz, Márcia , Planté‐Bordeneuve, Violaine , Berk, John L. , Conceição, Isabel , Hughes, S. G., Gertz, Morie A. , investigators, for the NEURO‐TTR open‐label extension

Mayo Clinic

European Journal of Neurology | April 28, 2020 | Volume: 27 | Issue: 8 | Pages: 1374-1381

10.1111/ene.14285 | PMID 32343462 Get It

Background and purposeHereditary transthyretin (hATTR) amyloidosis causes progressive polyneuropathy resulting from transthyretin (TTR) amyloid deposition throughout the body, including the peripheral nerves. The efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of TTR protein production, were demonstrated in the pivotal NEURO‐TTR study in patients with hATTR polyneuropathy. Here, the long‐term efficacy and safety of inotersen are assessed in an ongoing open‐label extension (OLE) study.MethodsPatients who completed NEURO‐TTR were eligible to enroll in the OLE (NCT02175004). Efficacy assessments included the modified Neuropathy Impairment Score plus seven neurophysiological tests composite score (mNIS + 7), the Norfolk Quality of Life – Diabetic Neuropathy (Norfolk QOL‐DN) questionnaire total score and the Short‐Form 36 Health Survey (SF‐36) Physical Component Summary (PCS) score. Safety and tolerability were also assessed.ResultsOverall, 97% (135/139) of patients who completed NEURO‐TTR enrolled in the OLE. Patients who received inotersen for 39 cumulative months in NEURO‐TTR and the OLE continued to show benefit; patients who switched from placebo to inotersen in the OLE demonstrated improvement or stabilization of neurological disease progression by mNIS + 7, Norfolk QOL‐DN and SF‐36 PCS. No new safety concerns were identified. There was no evidence of increased risk for grade 4 thrombocytopenia or severe renal events with increased duration of inotersen exposure.ConclusionInotersen slowed disease progression and reduced deterioration of quality of life in patients with hATTR polyneuropathy. Early treatment with inotersen resulted in greater long‐term disease stabilization than delayed initiation. Routine platelet and renal safety monitoring were effective; no new safety signals were observed.